Check patentability & draft patents in minutes with Patsnap Eureka AI!

Use of urushiol compound in preparing medicine for inhibiting liver tissue fibrosis

A technology of liver tissue and compounds, applied to active ingredients of hydroxyl compounds, drug combinations, digestive system, etc.

Active Publication Date: 2015-08-05
SOUTHERN MEDICAL UNIVERSITY +1
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, except interferon α, which has a definite curative effect on liver fibrosis caused by chronic hepatitis C virus, there is no other definite and effective drug for the treatment of liver fibrosis. Therefore, it is necessary to develop new drugs that inhibit liver tissue fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of urushiol compound in preparing medicine for inhibiting liver tissue fibrosis
  • Use of urushiol compound in preparing medicine for inhibiting liver tissue fibrosis
  • Use of urushiol compound in preparing medicine for inhibiting liver tissue fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1: Urushiol (GQ-5) Toxicology Experiment

[0031] 1. Experimental animals: Kunming mice, male, weighing 25-30g, SPF grade. The animals were first weighed and numbered, and 30 healthy mice weighing 25-30 g were selected and randomly divided into 3 groups, 10 in each group. Including 200mg / Kg body weight, 400mg / Kg body weight, and 800mg / Kg body weight.

[0032] 2. Treatment of each group

[0033] 200mg / Kg body weight group: intraperitoneally inject 200mg / Kg body weight GQ-5 once a day;

[0034] 400mg / Kg body weight group: intraperitoneally inject 400mg / Kg body weight GQ-5 once a day;

[0035] 800mg / Kg body weight group: intraperitoneally inject 800mg / Kg body weight GQ-5 once a day.

[0036] 3. Experimental process

[0037] Raise in separate cages for 7 days. Observe the death of mice.

[0038] 4. Experimental results

[0039] No mice in any group died. It suggested that GQ-5 had no lethal toxicity.

Embodiment 2

[0040] Example two: GQ-5 inhibits liver tissue fibrosis in mice injected with carbon tetrachloride intraperitoneally

[0041] 1. Experimental animals: C57BL-6J mice, male, weighing 20-25g, SPF grade. First weigh and number the animals, select 50 healthy mice weighing 20-25 g, and randomly divide them into 10 groups, 10 in each group. Including normal control group, negative control group, positive control group and medication group.

[0042] 2. Treatment of each group

[0043]Carbon tetrachloride was dissolved in olive oil (final concentration 10%). GQ-5 is dissolved in pure water containing 5% propylene glycol, and the dosage is 40mg / Kg body weight.

[0044] 1) Normal control group: normal feeding for 4 weeks

[0045] 2) Negative control group: intraperitoneal injection of olive oil at 5ml / Kg body weight every Tuesday and Thursday for 4 weeks

[0046] 3) Positive control group: 10% ethanol was injected intraperitoneally at 5ml / Kg body weight every Monday, Wednesday and...

Embodiment 3

[0068] Example 3: Medicinal Salt of Urushiol (GQ-5)

[0069] The urushiol (GQ-5) of the present invention is reacted with an organic acid (for example, tartaric acid, citric acid, formic acid, oxalic acid, etc.) to generate an organic acid salt of urushiol (GQ-5).

[0070] The organic acid salt of urushiol (GQ-5) is produced by reacting urushiol (GQ-5) described in the present invention with inorganic acid (for example, hydrochloric acid, sulfuric acid, phosphoric acid, etc.).

[0071] Urushiol (GQ-5) and its pharmaceutically acceptable salts can be used in the preparation of pharmaceutical preparations in the following examples.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of a urushiol compound to preparation of a drug for inhibiting fibering of liver tissue, and particularly provides a urushiol compound shown in the structural formula 1 and application of medical salt of the urushiol compound in preparation of a drug for inhibiting fibering of liver tissue. The urushiol compound provided by the invention has a good effect of inhibiting the fibering of liver tissue and is free of fatal toxic and side effects. The urushiol compound and the medical salt provided by the invention can be prepared into an oral agent or an injection type medicinal preparation for inhibiting the fibering of liver tissue.

Description

technical field [0001] The invention relates to the use of a traditional Chinese medicine extract in preparing a medicine for inhibiting liver tissue fibrosis, in particular to the use of an urushiol compound in preparing a medicine for inhibiting liver tissue fibrosis. Background technique [0002] Many chronic liver diseases (such as viral hepatitis, alcoholic liver disease, nonalcoholic steatohepatitis, etc.) manifest as liver tissue fibrosis, manifested as extracellular matrix protein (collagen, fibronectin) deposition, fibrotic scar formation, Then pseudolobule formation, liver cirrhosis, until liver cell dysfunction, liver failure, portal hypertension. Liver fibrosis is a common pathway for chronic liver disease to progress to liver failure. Inhibition of liver tissue fibrosis can undoubtedly effectively inhibit the progression of chronic liver disease. At present, except interferon α, which has a definite curative effect on liver fibrosis caused by chronic hepatitis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/05A61P1/16
Inventor 侯凡凡程永现聂静艾军郭勤
Owner SOUTHERN MEDICAL UNIVERSITY
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com